Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 10 IN PLASTIC CONTAINER.
AMINOSYN-HBC 7% vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-HBC 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, supporting anabolism and tissue repair in patients with high metabolic stress.
This combination product provides parenteral nutrition. Dextrose supplies calories and energy. Electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate) maintain fluid and electrolyte balance. Amino acids provide nitrogen for protein synthesis.
Intravenous infusion; typical adult dose: 1.0-1.5 g/kg/day of amino acids, administered as a continuous infusion over 12-24 hours.
Intravenous infusion: 500 mL to 2 L per day, typically at 42 mL/hour, providing 4.25% amino acids and 10% dextrose for parenteral nutrition.
None Documented
None Documented
Not applicable; amino acids are continuously metabolized and recycled. For individual amino acids, terminal half-life ranges from minutes to hours depending on metabolic demand.
Not applicable as a single entity; components have independent kinetics: amino acids ~0.5-2 h (endogenous turnover), dextrose ~2 h (glucose), electrolytes follow renal clearance.
Renal: >90% as amino acids and metabolites; minimal biliary/fecal elimination.
Renal: >95% as unchanged amino acids, dextrose (metabolized to CO2 and water), and electrolytes. Fecal/biliary: negligible (<1%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution